Bristol-Myers Squibb Company has announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s disease.
The randomized, double-blind, placebo-controlled study (CN156-013) demonstrated that BMS-708163 doses below 100 mg/day provide a potential therapeutic window for further evaluation in Phase III registrational studies. The study results were presented at the 2011 Alzheimer’s Association International Conference (AAIC).
Of the four BMS-708163 doses evaluated in the study (25 mg, 50 mg, 100 mg and 125 mg/day), doses below 100 mg/day demonstrated acceptable tolerability profiles for further development and were associated with discontinuation rates comparable with placebo. BMS-708163 doses at or above 100 mg were associated with higher discontinuation rates, most commonly due to gastrointestinal and dermatological side effects.
BMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta (AÎ²) synthesis. AÎ² is hypothesized to play a central role in the development of Alzheimer’s disease. In healthy people, AÎ² breaks down and is eliminated, but in people with Alzheimer’s disease, AÎ² accumulates and forms “amyloid plaques” in the brain. While the chain of events that lead to the development of Alzheimer’s is still unclear, the accumulation of AÎ² and the resulting formation of amyloid plaques are considered hallmarks of the disease pathology.
“The safety and tolerability results of this Phase II study in mild-to-moderate Alzheimer’s disease support the further clinical evaluation of Bristol-Myers Squibb’s gamma secretase inhibitor,” said Stephen Salloway, Professor of Neurology and Psychiatry at Brown University.
“The data also provide clear direction to continue testing of the amyloid hypothesis as we look for ways to address this devastating illness,”
This Phase II study (CN156-013) in mild-to-moderate Alzheimer’s disease met its primary objective of identifying safe and tolerable doses of BMS-708163, providing a potential therapeutic window for intervention at doses less than 100 mg/day that warrants testing in Phase III registrational studies. The study was not adequately powered to determine the efficacy of BMS-708163.
For treated patients, the discontinuation rates for any reason were placebo: 19%, BMS-708163 25 mg: 21%, 50 mg: 28%, 100 mg: 41%, and 125 mg: 48%. The most common gastrointestinal adverse events observed in this study were diarrhea (placebo: 7%, 25 mg: 24%, 50 mg: 12%, 100 mg: 27%, 125 mg: 20%) and nausea (placebo: 0%, 25 mg: 5%, 50 mg: 2%, 100 mg: 27%, 125 mg: 13%). The most common skin-related adverse events observed in this study were rash (placebo: 0%, 25 mg: 2%, 50 mg: 12%, 100 mg: 27%, 125 mg: 43%) and pruritis (placebo: 0%, 25 mg: 0%, 50 mg: 2%, 100 mg: 10%, 125 mg: 20%).
Signals that occurred at greater rates in treatment groups compared to placebo and that were identified for ongoing monitoring included: reversible glucosuria with no changes in serum glucose, asymptomatic MRI findings (amyloid-related imaging abnormalities), gastrointestinal ulcers, rash, pruritis, and non-melanoma skin cancer. The overall incidence of serious adverse events was similar across placebo and all treatment groups (placebo: 19%; 25 mg: 17%; 50 mg: 16%; 100 mg: 15%; 125 mg: 15%). There were no deaths reported in the study.
Safety was assessed every two weeks during the treatment period.